
Opinion|Videos|August 1, 2024
Therapeutic Response and Disease Progression
Author(s)Justin Oldham, MD, MS
An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can multidisciplinary care be optimized when treating patients with IPF?
- Describe the therapeutic response and disease progression of patients taking standard of care therapies (pharmacologic and non-pharmacologic).
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
OpenAI for Healthcare Aims to Streamline Clinical Workflows, Reduce Administrative Burden
2
Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data
3
J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort
4
Postpandemic Nursing Home Capacity Declines Tied to Longer Hospital Stays, Increased Patient Travel
5






























































